Consolidating adverse event databases is a smart move, but without public education, real-time transparency risks becoming ...
It’s out with the old, in with the new at the FDA as the agency is unveiling a new adverse events monitoring system that joins several reporting systems into one unified platform, an effort that’s ...
As Department of Health and Human Services (HHS) and FDA leadership continue to look for ways to boost transparency and reshape the U.S' healthcare infrastructure, the U.S. drug regulator has unveiled ...
Adverse Drug Event Reporting: The Roles of Consumers and Health-Care Professionals: Workshop Summary
Adverse reactions to prescription drugs (adverse drug events, or ADEs) are quite common and usually do little harm to patients. But in a small percentage of cases, they can have serious consequences ...
Please provide your email address to receive an email when new articles are posted on . The FDA Adverse Event Reporting System will now host daily publications, instead of quarterly. The agency’s goal ...
To increase transparency, the agency is publishing data from the FDA Adverse Event Reporting System daily rather than quarterly. (HealthDay News) — The U.S. Food and Drug Administration is now ...
Access to patient-reported outcome (PRO) data significantly improved providers' consistency in assessing adverse events in patients with cancer, with the greatest improvements observed for ...
The FDA has launched a single public platform for adverse event reports related to drugs, biologics, vaccines, cosmetics and animal food. The Adverse Event Monitoring System will publish reports in ...
The FDA has received hundreds of adverse event reports after people used compounded GLP-1 drugs for weight loss. Compounded GLP-1 drugs aren’t reviewed by the FDA for safety or effectiveness. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results